|
⚲
|
| Keyboard |
| JFL Capital Management LLC
✚
|
|
|---|---|
| CRD # | 174202 |
| SEC # | 801-110801 |
| CIK # | 0001770400, 0001687888 |
| AUM | |
| Employees | 3 (67% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 512-761-4500 |
| Address | 1415 Rr 620 South Lakeway, TX 78734 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($M) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/23/2021) [Brochure] |
|---|
Item 5 – Fees and Compensation
A. Fee Schedule
The fees and compensation payable to JFL are negotiable and vary among its Clients.
However, the range of compensation is generally as follows:
1. Management Fee
The Firm typically receives a monthly asset-based management fee calculated as a
percentage of each Investor’s capital account, payable monthly in advance. The management
fee is generally 2.0%.
2. Incentive Allocation
The Firm generally receives an incentive allocation equal to a percentage of the net income
allocated to each Investor for the year, but only to the extent net income allocated to that
Investor exceeds any cumulative losses that were allocated to that Investor for earlier periods
and that have not been recovered (a “high water mark”). This incentive allocation is generally
25% and is typically made at the end of each calendar year.
The incentive allocation will only be charged to accounts of those Investors who are “qualified
clients” as defined in Rule 205-3 of the Investment Advisers Act of 1940, as amended
(“Advisers Act”), in accordance with applicable state law.
3. Fee Comparison
The expenses of the Client, including the management fee and incentive allocation may
constitute a higher or lower percentage of average net assets than would be found in other
investment vehicles.
B. Payment of Fees
Management fees, incentive allocations, and third-party fees (discussed below) are deducted
from Client assets. Management fees, which are paid in advance, are withdrawn at the
beginning of the month. Incentive allocations are allocated as of the last business day of the
calendar year and as of any date on which an Investor makes a withdrawal or receives a
distribution from such Investor’s capital account(s).
C. Third-Party Fees
The Client shall pay such costs and expenses as the Firm shall reasonably determine to be
necessary, appropriate, advisable or convenient to carry on its business and realize its
objective, including: (i) management fees; (ii) all general investment expenses (i.e., expenses
which the Firm reasonably determines to be directly related to the investment of the Client’s
assets); (iii) all administrative, legal, accounting, auditing, record-keeping, tax form
preparation, compliance and consulting costs and expenses; (iv) fees, costs and expenses of
third-party service providers that provide such services; and, (v) any extraordinary expenses.
JFL’s fees are exclusive of brokerage commissions, transaction fees, and other related costs
and expenses which shall be incurred by the Clients. Such charges, fees and commissions are
Part 2A of ADV:
JFL Capital Management LLC Brochure
exclusive of and in addition to the Firm’s fees and compensation, and the Firm shall not
receive any portion of these commissions, fees, and costs.
Please see Item 12 of this Brochure regarding brokerage.
D. Prepayment of Fees
Prepaid management fees are earned within one month after payment.
E. Outside Compensation for the Sale of Securities
Neither JFL nor its supervised persons accept compensation for the sale of securities or other
investment products outside of its association with JFL.
The foregoing discussion in Items 5 represents JFL’s basic compensation
arrangements. The management fees and incentive allocations described above are
structured to comply with Rule 205-3 under the Advisers Act and applicable state laws.
Fees and other compensation are negotiable in certain circumstances and
arrangements with any particular Investor may vary. Although the Firm believes its
fees are competitive, lower fees for comparable services may be available from other
investment advisers. |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/23/2021) [Brochure] |
|---|
Item 7 – Types of Clients
JFL provides investment advice and portfolio management services to the Clients.
JFL may in the future provide the same or similar services to other privately placed
investment funds and/or separately managed accounts.
The Firm intends to restrict the number of Investors in the Funds and will offer Interests only
through non-public transactions in order to maintain the Funds’ exclusion from “investment
company” status under the Investment Company Act of 1940, as amended (the “Investment
Company Act”).
Part 2A of ADV:
JFL Capital Management LLC Brochure
Prospective Investors must meet eligibility criteria, and are subject to certain withdrawal
requirements and limitations. Prospective Investors are encouraged to thoroughly review
the Funds’ Constituent Documents, which set forth all of the terms in detail. Though the
Clients generally pursue the same strategy, offering terms may differ.
The Funds. Each Investor generally must be an “accredited investor” (as defined in Regulation
D under the Securities Act of 1933), an Investor who is eligible to enter into a performance
fee arrangement under state and/or federal law, as applicable, and must meet other criteria
as specified in the Constituent Documents. The minimum initial investment is $250,000, and
the minimum additional investment is $50,000, subject to waiver at the discretion of JFL.
Separately Managed Accounts. Terms for separately managed accounts are generally similar
to the Funds, but can be negotiated on a case by case basis and may differ from those of the
Funds. Account minimums are negotiable and vary among these Clients. |
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | JFL Partners Fund LP | [2017-06-12] | 10.8 M | 63.0 M |
| Filed 2015-12-11 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 2 | 63.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 1 | 152.0 |
| (n) Other | 0 | 0.0 |
| Total | 3 | 215.0 |
| By Discretionary | ||
| Discretionary | 3 | 215.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 3 | 215.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 13.0 | |
| United States Persons | 202.0 | |
| Total | 3 | 215.0 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Joseph Lawler | Executive Officer | 19 | 3 | |
| Jfl Capital Management LP | Executive Officer | 4 | 2 | |
| Jfl Capital Holdings LLC | Executive Officer | 4 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001687888] | |
| 4 | [0001687888] | |
| SC 13D | [0001687888] | |
| SC 13G | [0001687888] | |
| 3 | [0001770400] | |
| 4 | [0001770400] | |
| SC 13G | [0001770400] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.1B |
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 254900KN8ADSZGJS6Y34 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| JFL Capital Management LLC | |
| Lawler Joseph F | |
| JFL Partners Fund LP | |
| Merrimack Pharmaceuticals Inc | |
| JFL Capital Holdings LLC | |
| JFL Capital Management LP | |
| GYRE Therapeutics Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Merrimack Pharmaceuticals Inc MACK
Common Stock
|
2019-07-02 | Buy | 7,024 | $5.85 | 41,090 |
|
Merrimack Pharmaceuticals Inc MACK
Common Stock
|
2019-07-02 | Buy | 10,107 | $5.85 | 59,126 |
|
Merrimack Pharmaceuticals Inc MACK
Common Stock
|
2019-07-01 | Buy | 5,659 | $6.00 | 33,954 |
|
Merrimack Pharmaceuticals Inc MACK
Common Stock
|
2019-07-01 | Buy | 3,934 | $6.00 | 23,604 |
|
Merrimack Pharmaceuticals Inc MACK
Common Stock
|
2019-06-28 | Buy | 13,902 | $5.95 | 82,717 |
|
Merrimack Pharmaceuticals Inc MACK
Common Stock
|
2019-06-28 | Buy | 9,662 | $5.95 | 57,489 |
|
Merrimack Pharmaceuticals Inc MACK
Common Stock
|
2019-04-08 | Buy | 6,484 | $5.73 | 37,153 |
|
Merrimack Pharmaceuticals Inc MACK
Common Stock
|
2019-04-08 | Buy | 4,506 | $5.73 | 25,819 |
|
Merrimack Pharmaceuticals Inc MACK
Common Stock
|
2019-04-05 | Buy | 26,288 | $5.95 | 156,414 |